Data / Research funding / Maryland / Advanced Bioscience Laboratories, Inc.
Advanced Bioscience Laboratories, Inc.: 13 NIH awards ($76.8M), fiscal years 2021 to 2026
Advanced Bioscience Laboratories, Inc. in Kensington, MD is funded under 13 NIH awards ($76.8M) in the NIH and NSF award files, read 2026-11-03. NIH fiscal years 2021 to 2025; NSF fiscal years 2022 to 2026.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- UEI
- MK4QC9EKZXG8
- State
- Maryland
Awards
13 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Production of Aluminum Based Adjuvants | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $34,078,534 | September 20, 2017 | December 31, 2026 | MACK, FRED | reporter.nih.gov |
| CGMP MANUFACTURE OF VHCA8* FOR THE TREATMENT OF PAIN | NIH | National Institute on Drug Abuse | 2022 to 2025 | $11,758,351 | March 11, 2024 | April 29, 2027 | MAYER, CHRISTINA | reporter.nih.gov |
| Expertise in Using Bitter Taste Receptor Blockers to Improve the Palatability of Pediatric Medicines: Blocker Discovery | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $9,584,357 | September 30, 2025 | September 29, 2026 | SILVERA, PETER | reporter.nih.gov |
| Comprehensive Resources for HIV Microbicides and Biomedical Prevention: Quality Assurance/ Quality Control (QA/QC) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $8,076,617 | July 15, 2022 | July 14, 2023 | SILVERA, PETER | reporter.nih.gov |
| Task V31: Process Development for a Panfungal Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,346,445 | January 20, 2023 | July 30, 2025 | FOUTS, TIM | reporter.nih.gov |
| Production of cGMP Native Flexibly Linked HIV-1 Envelope Protein | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,709,483 | September 12, 2016 | March 31, 2028 | FOUTS, TIMOTHY | reporter.nih.gov |
| Feasibility for Development of a Liposome/LNP Displaying an HIV Env Trimer Protein and Containing/Incorporating an mRNA | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $1,863,405 | August 31, 2024 | August 27, 2028 | FOUTS, TIMOTHY R | reporter.nih.gov |
| Comparison of Bivalent vs Pentavalent Subtype C Envelope HIV-1 Vaccine Efficacy Following Mucosal Virus Challenge | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,657,533 | August 15, 2016 | June 30, 2021 | SILVERA, PETER | reporter.nih.gov |
| Task X11: Product Development Plans and Feasibility Assessments | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $380,121 | November 6, 2014 | May 1, 2020 | RICHARDSON, JAMES | reporter.nih.gov |
| Manufacture of a Vaccine Targeting Frame-Shift Mutations Characteristic of Tumors with Microsatellite Instability | NIH | National Cancer Institute | 2021 to 2023 | $179,447 | September 19, 2019 | December 31, 2023 | TEBEAU, BETH | reporter.nih.gov |
| IGF::OT::IGF SMARTT BIOLOGICS PRODUCTION FACILITY (PF); BASE PERIOD; FY16; AMT $2,069,079; CAN 8470205 | NIH | National Heart, Lung, and Blood Institute | 2023 | $162,809 | March 1, 2016 | February 7, 2019 | ISHIKAWA, PHILLIP | reporter.nih.gov |
| Product Development Plan for Cholera Product | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $9,217 | September 11, 2017 | April 13, 2018 | ZIV, SANDALON | reporter.nih.gov |
| TASK A: NIAID Preclinical Services for AMR Diagnostics Development - Product Development Processes and Documentation | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $7,000 | June 20, 2023 | June 19, 2030 | MAYER, CHRISTINA | reporter.nih.gov |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 5 | $7,336,191 | 0 | $0 |
| 2024 | 8 | $23,704,625 | 0 | $0 |
| 2023 | 11 | $23,706,561 | 0 | $0 |
| 2022 | 6 | $8,990,185 | 0 | $0 |
| 2021 | 7 | $13,075,757 | 0 | $0 |
Topics of its NIH awards
- Infectious Diseases
- Prevention
- Biotechnology
- Immunization
- Vaccine Related
- HIV/AIDS
- Translational Research
- Vaccine Related - AIDS
- Antimicrobial Resistance
- Emerging Infectious Diseases
- Biodefense and Related Countermeasures
- Genetics
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.